Today: 9 July 2026
CNQ drops even as TSX heads higher in oil slide
25 May 2026
2 mins read

CNQ drops even as TSX heads higher in oil slide

Calgary, May 25, 2026, 10:01 MDT

Canadian Natural Resources shares lost around 3% in Toronto on Monday, lagging the record run in Canada’s main stock index. Oil prices fell as traders eyed possible relief from U.S.-Iran talks. The stock hovered near C$65.12, off 3.16%. The S&P/TSX composite climbed about 1%.

Canadian Natural has turned into a direct way to play oil-sands cash as the country’s biggest oil and gas producer, which makes the move important for investors. West Texas Intermediate crude, the U.S. benchmark, dropped around 5% to $91.75 a barrel. Brent crude lost 4.8% to $98.57, according to Reuters.

Toronto stocks traded as usual with the market open. TMX’s calendar puts U.S. Memorial Day on May 25, which comes with special settlement rules for U.S.-dollar securities. Its Canadian 2026 holiday list has Victoria Day for May 18, with the next Canadian market holiday set for July 1.

S&P/TSX set a record high, Reuters reported, as miners gained and inflation fears eased. Energy lagged, falling 2.1% to become the only major TSX sector down on the day. Brian Madden, chief investment officer at First Avenue Investment Counsel, said “a non-zero chance” the conflict ends was enough to boost stocks and send oil lower. Reuters

Suncor Energy dropped 2.12% to C$91.05 on the TSX, with Cenovus Energy also down 2.35% to C$40.51. Both stocks tracked moves in crude. Market data via .

Canadian Natural shares fell less than three weeks after reporting a solid first quarter. The company turned in adjusted net earnings of C$2.4 billion. Adjusted funds flow was C$4.4 billion. Production came in at about 1.64 million BOE/d, with BOE/d converting oil and gas output into one oil-based unit.

Shareholder returns are still the main driver for the stock. Canadian Natural said it gave back about C$1.5 billion to shareholders in the first quarter by way of dividends and buybacks, meaning it bought back its own shares. CFO Victor Darel said returns would go to “100% of free cash flow” after net debt falls to C$13 billion. Free cash flow is what’s left after capital spending. TMX Newsfile

Canadian Natural’s management is linking oil-sands expansion to new pipeline projects. Speaking to analysts this month, President Scott Stauth said the company “needed a new West Coast pipeline to grow the oil sands in a significant way.” Reuters said the 150,000 bpd Jackpine expansion is still on pause as the company waits for more visibility on pipeline capacity. Reuters

Still, the downside is clear. If talks between the U.S. and Iran collapse, crude prices could bounce and help producers. If a deal sticks, and more oil passes through the Strait of Hormuz, crude’s risk premium might fall further. Kyle Rodda, senior financial market analyst at Capital.com, said Iran’s nuclear program and grip on the Strait are “potential obstacles.” Reuters

CNQ shares aren’t really trading on their dividend history right now, but on whatever crude moves next. That leaves the stock open to swings: if oil prices drop, that’s good news for inflation and the TSX, but it takes the shine off Canadian producers that got a lift from higher war premiums.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Virax Biolabs Jumps 183% After UK Unit Signs Fosun Diagnostics Supply Deal
    July 9, 2026, 1:27 PM EDT. Shares of Virax Biolabs Group (NASDAQ: VRAX) soared 183% to $9.00 on July 9. The spike came after its UK arm reached an exclusive supply deal with Fosun Diagnostics covering Southeast Asia, including Thailand, Vietnam and Singapore. The agreement focuses on ImmuneSelect, its immune-profiling research product. Virax is looking to move past research-only offerings and grow in the commercial market. The company reported just $12,423 in revenue for fiscal 2026 and a net loss of $5 million. CEO James Foster called the deal a key step. Fosun MedTech, part of Fosun Pharma, which posted $5.8 billion in 2025 revenue, said Virax's platform is a strong research pick. The move follows a one-for-25 reverse split done to keep its Nasdaq listing.
BlackBerry Rallies 19%; Quiet Holiday Week Could Test QNX Momentum
Previous Story

BlackBerry Surges, Eyes on Tuesday for Next Move

Momentus Shares Soar After $200 Million Filing
Next Story

Momentus Shares Soar After $200 Million Filing

Go toTop